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Is the risk of cancer in Australia 
overstated? The importance of 
competing mortality for 
estimating lifetime risk 
Abstract 
Objectives: To calculate lifetime risks of cancer diagnosis and cancer-specific death, 
adjusted for competing mortality, and to compare these estimates with the corresponding 
risks published by the Australian Institute of Health and Welfare (AIHW). 
Design, setting: Analysis of publicly available annual AIHW data on age-specific cancer 
incidence and mortality — for breast cancer, colorectal cancer, prostate cancer, melanoma 
of the skin, and lung cancer — and all-cause mortality in Australia, 1982–2013. 
Outcome measures: Lifetime risks of cancer diagnosis and mortality (to age 85), adjusted 
for competing mortality. 
Results: During 1982–2013, AIHW estimates were consistently higher than our competing 
mortality-adjusted estimates of lifetime risks of diagnosis and death for all five cancers. 
Differences between AIHW and adjusted estimates declined with time for breast cancer, 
prostate cancer, colorectal cancer, and lung cancer (for men only), but remained steady for 
lung cancer (women only) and melanoma of the skin. In 2013, the respective estimated 
lifetime risks of diagnosis (AIHW and adjusted) were 12.7% and 12.1% for breast cancer, 
18.7% and 16.2% for prostate cancer, 9.0% and 7.0% (men) and 6.4% and 5.5% (women) 
for colorectal cancer, 7.5% and 6.0% (men) and 4.4% and 4.0% (women) for melanoma of 
the skin, and 7.6% and 5.8% (men) and 4.5% and 3.9% (women) for lung cancer. 
Conclusion: The method employed in Australia to calculate the lifetime risks of cancer 
diagnosis and mortality overestimates these risks, especially for men. 
 
Summary box 
The known: The Australian Institute of Health and Welfare (AIHW), like many cancer 
registries, calculates cumulative risk from cross-sectional data to estimate lifetime risks of 
cancer diagnosis and mortality. Its method assumes there are no competing causes of 
death, which may lead to overestimation of lifetime risk. 
The new: Adjusting for competing mortality reduced the estimated lifetime risks of cancer 
diagnosis and cancer-specific mortality for the five most common cancers in Australia. 
The implication: Estimates of cancer-specific risk are widely circulated in awareness 
campaigns and for promoting early detection activities, and adjusted estimates would be 
more appropriate for informing choices by individuals. 
Cancer (46 307 deaths in 20161) and coronary heart disease (19 077 deaths in 20162) are 
the leading causes of death in Australia. An estimated 470 new cancers were diagnosed and 
161 cancer deaths recorded per 100 000 Australian adults in 2017; the five most frequently 
diagnosed cancers were breast cancer, colorectal cancer, prostate cancer, melanoma of the 
skin, and lung cancer.3 State-based registries record and submit cancer incidence and 
mortality data to the Australian Institute of Health and Welfare (AIHW), which compiles 
these data annually for the Australian Cancer Database. The International Agency for 
Research on Cancer grades the quality of these data as “A”, the highest level on their scale.4 
AIHW Australian Cancer Database reports are an important source of information on 
cancer epidemiology and guide initiatives for improving cancer prevention, screening, 
diagnosis, and treatment at the local, state, and national levels.5 
The AIHW calculates cumulative risk by using cross-sectional data to estimate the 
lifetime risks of cancer diagnoses. These risk estimates are important, as they are freely 
accessible to the public, clinicians, and organisations that employ them for a range of 
purposes. The AIHW first calculates the risk of being diagnosed with a particular cancer 
for each 5-year age group interval, conditional on surviving to the beginning of that 
 
interval; these risks are then summed to obtain an overall estimate of the lifetime 
probability of cancer.3,6 This method overestimates the lifetime probability of cancer when 
compared with methods that account for competing mortality risk from non-cancer 
conditions.7-9  
We therefore hypothesised that the AIHW method overestimates lifetime cancer risks in 
Australia. In this study, we estimated the lifetime risks of cancer diagnosis and death for 
the five most common cancers in Australia, adjusted for competing mortality, and compared 
these estimates with the lifetime risks published by the AIHW. 
Methods 
We employed DevCan 6.7.5, freely available statistics software provided by the United 
States National Cancer Institute (https://surveillance.cancer.gov/devcan), to estimate the 
lifetime risks of diagnosis and mortality for breast cancer, prostate cancer, colorectal 
cancer, melanoma of the skin, and lung cancer, adjusted for competing mortality. DevCan 
6.7.5 applies a lifetable approach to analysing cross-sectional counts (or rates) of cancer-
specific incidence, cancer-specific deaths, all-cause deaths, and population numbers for sex 
and age group intervals from birth to the final years of life. The program estimates the 
probability of being diagnosed with a specific cancer within each age interval, conditional 
on being alive and cancer-free at the beginning of the interval, in a unified competing risks 
framework.10 We described the statistical methods applied by the software in greater detail 
in our article on the estimated lifetime risk of prostate cancer overdiagnosis in Australia.11 
Sex- and age-specific cancer incidence and mortality and all-cause mortality counts for 
the calendar years 1982–2013 were obtained from the AIHW.12-17 We extracted data for 
invasive cancer only and generated life tables to calculate the cumulative risks of diagnosis 
and death for each cancer for each calendar year, to age 85 years (the upper age limit for 
calculating lifetime risk used by the AIHW). We estimated lifetime risk adjusted for 
competing mortality as a percentage risk. For colorectal cancer, lung cancer, and melanoma, 
we estimated risks separately for women and men. We then compared our estimates with 
the estimates published by the AIHW. One of two authors (ACB, KL) undertook the 
calculations for a specific cancer type, and the other independently estimated the 
corresponding lifetime risks for the years 1985, 1990, 1995, 2000, 2005, and 2010 as a 
cross-check. 
Ethics approval 
Approval by a Human Research Ethics Committee was not required for our analysis of 
publicly available aggregated population data. 
Results 
For all cancers and years examined, the published AIHW lifetime risks of cancer diagnosis 
(Box 1; Supporting Information, tables 1–5) and mortality (Box 1) were higher than our 
calculated lifetime risks, adjusted for competing mortality. 
Invasive breast cancer (women) 
Both the AIHW estimates and our adjusted estimates of lifetime risk of diagnosis increased 
markedly from 1993, corresponding to the introduction of the national mammography 
program in Australia. The difference between the AIHW estimate and our adjusted estimate 
declined from 1.5 percentage points (1982) to 0.6 percentage point (2013), and the 
difference between AIHW and adjusted risk of mortality estimates declined from 0.8 
percentage point (1982) to 0.4 percentage point (2013) (Box 1, Box 2). 
Prostate cancer (men) 
Both the AIHW estimates and our adjusted estimates of lifetime risk of diagnosis increased 
markedly during the early 1990s, corresponding to the introduction of the prostate-specific 
antigen (PSA) test. The difference between the AIHW estimate and our adjusted estimate 
was the largest for any of the cancers examined, but declined from 6.4 percentage points in 
1982 to 2.5 percentage points in 2013. The differences between mortality estimates were 
 
similarly the greatest for any cancer, but declined from 3.0 percentage points (1982) to 0.9 
percentage point (2013) (Box 1, Box 3). 
Colorectal cancer (men and women) 
The lifetime risks of colorectal cancer diagnoses remained steady for both men and women 
between 1982 and 2013. The differences between the AIHW and our competing mortality-
adjusted estimates declined from 4.0 percentage points (1982) to 2.0 percentage points 
(2013) for men, and from 1.8 percentage points (1982) to 0.9 percentage point (2013) for 
women. Differences between the estimates of lifetime mortality risk also declined, from 
2.5 percentage points (1982) to 0.7 percentage point (2013) for men, and from 1.1 
percentage points (1982) to 0.3 percentage point (2013) for women (Box 1, Box 4). 
Invasive melanoma of the skin (men and women) 
The lifetime risks of a melanoma diagnosis increased for both men and women between 
1982 and 2013. The differences between the AIHW estimate and our adjusted estimate of 
lifetime risk of melanoma diagnosis were the smallest for any of the cancers examined, and 
remained steady over time: for men, 1.0 percentage point in 1982, 1.1 percentage point in 
2013; for women, 0.4 percentage point in 1982, 0.4 percentage point in 2013. The 
differences in estimates of lifetime mortality risk were also the smallest for any cancer and 
steady over time: for men, 0.3 percentage point in 1982, 0.4 percentage point in 2013; for 
women, 0.1 percentage point in 1982, 0.0% in 2013 (Box 1, Box 5). 
Lung cancer (men and women) 
The lifetime risks for a lung cancer diagnosis increased for women but declined for men 
between 1982 and 2013. For men, the difference between the AIHW estimate and our 
adjusted estimate of lifetime risk of diagnosis declined from 4.8 percentage points (1982) 
to 1.8 percentage points (2013); the difference between the estimates for lifetime mortality 
risk declined from 4.9 percentage points (1982) to 1.6 percentage points (2013). For 
women, the differences in the estimates of lifetime risk of diagnosis (0.6 percentage point 
in 1982, 0.7 percentage point in 2013) and of mortality (0.5 percentage point in 1982, 0.5 
percentage point in 2013) were steady across time (Box 1, Box 6). 
Discussion 
We found that AIHW estimates of the lifetime risks of diagnosis of or death from breast 
cancer, prostate cancer, colorectal cancer, melanoma of the skin, and lung cancer in 
Australia during 1982–2013 were consistently higher than estimates adjusted for competing 
mortality. The AIHW estimates were sometimes substantially higher; for example, the 
AIHW-estimated lifetime risk for prostate cancer in 1993 was 22.5%, the competing 
mortality-adjusted risk 14.4%. In 2013, the differences between lifetime risk of diagnosis 
estimates ranged between 0.4 percentage point for melanoma in women and 2.5 percentage 
points for prostate cancer in men. 
For cancers for which the differences in estimated lifetime risk of a diagnosis exceeded 
1% in 1982 (breast, prostate, and colorectal cancer, and lung cancer in men), the differences 
declined over time. This finding may be explained by falling competing mortality from 
cardiovascular disease.18 For cancers for which the differences were 1.0 percentage point 
or less in 1982 (lung cancer in women, melanoma), the differences changed little. The 
differences in estimated lifetime risks of diagnosis and mortality were consistently smaller 
for women than men, which may be explained by greater competing mortality risk for men 
from other causes, such as cardiovascular disease.19 
We have reported estimates of lifetime risk as percentage risks, but health agencies and 
other organisations often communicate lifetime risks to the public as a natural frequency 
(ie, “one in x chance”). For example, Cancer Australia reports the current lifetime risk of 
prostate cancer for Australian men (to age 85) is 1 in 6,20 while the organisation “ManUp! 
Australia” describes it as 1 in 5.21 Risk communication studies suggest that this approach 
is not ideal for communicating risk; people have a clearer perception of risk when the 
denominator remains constant (eg, 1 in 10 v 2 in 10) rather than the numerator (eg, 1 in 10 
v 1 in 5).22 The AIHW publishes lifetime risk estimates both as natural frequencies and as 
percentage risks, and both formats are affected by correction or non-correction for 
 
competing risk; for example, the AIHW estimate for the lifetime risk of a prostate cancer 
diagnosis in 1993 was 1 in 4, while the risk after adjusting for competing mortality was 1 
in 7. 
Differences between AIHW and adjusted estimates of lifetime risk of cancer-specific risk 
and mortality will not be eliminated if the AIHW estimates are not adjusted for competing 
mortality. Although such adjustment is clearly useful, it relies upon the availability of good 
quality administrative data to estimate competing mortality risks; these data are available 
in many high income countries, including Australia, but they are not available for all 
populations. Unlike the current AIHW approach, the DevCan method requires additional 
data, such as cancer-specific and all-cause mortality, and this adds further complexity to 
calculating lifetime risk. Finally, by adjusting for competing mortality, it may become more 
difficult to infer the extent to which observed changes in cancer-specific risk are 
attributable to changes in risk factor prevalence, as opposed to variations in life expectancy 
resulting from changes in non-cancer causes of mortality.8 This problem, however, is not 
relevant to the primary purpose of lifetime risk estimates, which is to provide risk 
information to the Australian public, clinicians, and policymakers, not to explore the 
underlying causes of changes in risk. 
Our results indicate that cancer agencies, including the AIHW, may overestimate the 
risks of people being diagnosed with or dying from a particular cancer. We are, not, 
however, criticising the AIHW. The method used by the AIHW is employed by many cancer 
registries; further, software that facilitates accounting for competing risk was not available 
when AIHW began calculating lifetime risks. DevCan has since become freely available 
from the US National Cancer Institute, rendering accounting for competing mortality more 
convenient. DevCan software is employed by American and Canadian agencies for 
calculating lifetime cancer risks,23 and a different method is applied in the United Kingdom 
for the same purpose.24 
As lifetime risk estimates are widely cited in health promotion campaigns, they may 
cause public misperceptions of the risk of a cancer diagnosis or death. For example, lifetime 
cancer risk is used to increase awareness and to promote screening and other early detection 
activities by the Cancer Council Pink Ribbon campaign (breast and gynaecological cancers; 
https://www.pinkribbon.com.au), the Bowel Cancer Australia Red Apple Day (colorectal 
cancer; https://www.bowelcanceraustralia.org/red-apple-day), and the Prostate Cancer 
Foundation of Australia’s Get Checked Initiative (https://www.prostate.org.au/get-
checked). Overestimating the lifetime risk of a cancer may distort an individual’s 
perception of the potential benefits and harms of screening, leading them to undergo testing 
they may not otherwise have chosen. It is therefore important that cancer agencies consider 
the impact of their choice of statistical methods. 
Conclusion 
Our findings suggest that the method currently used by the AIHW to estimate the lifetime 
risks of diagnosis and death associated with the five most common cancers is likely to 
overestimate these risks. Australian agencies should consider adopting methods for 
adjusting for competing mortality when estimating lifetime risks, as currently employed in 
North America and the United Kingdom, to increase the accuracy of their estimates. 
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Box 1. Estimated lifetime risks of cancer diagnosis and mortality, Australia, 
1982–2013 




adjusted estimate (95% CI) AIHW estimate 
Competing mortality-
adjusted estimate (95% CI) 
Invasive breast cancer (women)    
1982 8.5% 7.0% (6.8–7.2%) 3.4% 2.6% (2.5–2.8%) 
1993 10.9% 9.6% (9.4–9.9%) 3.6% 2.9% (2.8–3.0%) 
2003 11.8% 10.9% (10.7–11.1%) 2.9% 2.5% (2.4–2.6%) 
2013 12.7% 12.1% (11.9–12.3%) 2.5% 2.1% (2.0–2.2%) 
Prostate cancer (men)      
1982 11.7% 5.3% (5.2–5.5%) 5.0% 2.0% (1.9–2.1%) 
1993 22.5% 14.4% (14.1–14.7%) 6.0% 3.1% (3.0–3.3%) 
2003 19.5% 15.0% (14.7–15.3%) 4.6% 2.9% (2.7–3.0%) 
2013 18.7% 16.2% (16.0–16.4%) 3.3% 2.4% (2.3–2.5%) 
Colorectal cancer (men)     
1982 8.8% 4.8% (4.7–5.0%) 5.0% 2.5% (2.4–2.7%) 
1993 9.7% 6.4% (6.3–6.6%) 4.6% 2.8% (2.7–2.9%) 
2003 10.0% 7.3% (7.1–7.5%) 3.7% 2.5% (2.4–2.6%) 
2013 9.0% 7.0% (6.8–7.2%) 2.6% 1.9% (1.8–2.0%) 
Colorectal cancer (women)    
1982 6.6% 4.8% (4.7–5.0%) 3.5% 2.4% (2.3–2.6%) 
1993 6.8% 5.4% (5.2–5.5%) 3.1% 2.3% (2.2–2.4%) 
2003 7.0% 5.8% (5.6–5.9%) 2.3% 1.8% (1.8–1.9%) 
2013 6.4% 5.5% (5.4–5.7%) 1.7% 1.4% (1.3–1.5%) 
Invasive melanoma of skin (men)    
1982 3.0% 2.0% (1.9–2.1%) 0.8% 0.5% (0.4–0.5%) 
1993 5.6% 4.0% (3.9–4.1%) 1.0% 0.7% (0.6–0.7%) 
2003 6.9% 5.3% (5.1–5.4%) 1.1% 0.8% (0.7–0.8%) 
2013 7.5% 6.0% (5.9–6.2%) 1.3% 0.9% (0.9–1.0%) 
Invasive melanoma of skin (women)    
1982 2.5% 2.1% (2.0–2.2%) 0.4% 0.3% (0.2–0.3%) 
1993 3.6% 3.1% (3.0–3.2%) 0.4% 0.3% (0.3–0.3%) 
2003 4.0% 3.6% (3.4–3.7%) 0.5% 0.4% (0.3–0.4%) 
2013 4.4% 4.0% (3.8–4.1%) 0.4% 0.4% (0.3–0.4%) 
Lung cancer (men)     
1982 11.3% 6.5% (6.3–6.7%) 10.8% 5.9% (5.8–6.1%) 
1993 9.8% 6.4% (6.2–6.5%) 9.0% 5.7% (5.5–5.8%) 
2003 8.5% 5.9% (5.7–6.1%) 7.2% 5.0% (4.8–5.1%) 
2013 7.6% 5.8% (5.6–5.9%) 5.9% 4.3% (4.2–4.5%) 
Lung cancer (women)     
1982 2.4% 1.8% (1.7–1.9%) 2.0% 1.5% (1.4–1.6%) 
1993 3.5% 2.7% (2.6–2.9%) 2.9% 2.3% (2.2–2.4%) 
2003 3.9% 3.2% (3.1–3.3%) 3.2% 2.6% (2.5–2.7%) 
2013 4.6% 3.9% (3.8–4.0%) 3.2% 2.7% (2.6–2.8%) 
AIHW = Australian Institute of Health and Welfare. 
  
 
Box 2. Lifetime risk of invasive breast cancer diagnosis for women, Australia, 
1982–2013 
AIHW = Australian Institute of Health and Welfare. 
95% confidence intervals are shown for the adjusted estimates. 
 
Box 3. Lifetime risk of prostate cancer diagnosis for men, Australia, 1982–2013 
AIHW = Australian Institute of Health and Welfare. 




Box 4. Lifetime risk of colorectal cancer diagnosis, Australia, 1982–2013 
AIHW = Australian Institute of Health and Welfare. 
95% confidence intervals are shown for the adjusted estimates. 
  
 
Box 5. Lifetime risk of melanoma of the skin diagnosis, Australia, 1982–2013 
AIHW = Australian Institute of Health and Welfare. 
95% confidence intervals are shown for the adjusted estimates. 
  
 
Box 6. Lifetime risk of lung cancer diagnosis, Australia, 1982–2013 
AIHW = Australian Institute of Health and Welfare. 
95% confidence intervals are shown for the adjusted estimates. 
